Literature DB >> 1009527

PHASE I clinical trial of an oral solution of VP-16-213.

N I Nissen, P Dombernowsky, H H Hansen, V Larsen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 1009527

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  14 in total

Review 1.  Chemotherapy in malignant mesothelioma: a review.

Authors:  A Krarup-Hansen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Antibacterial activities of antineoplastic agents.

Authors:  C A Bodet; J H Jorgensen; D J Drutz
Journal:  Antimicrob Agents Chemother       Date:  1985-09       Impact factor: 5.191

3.  Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide.

Authors:  J C Shah; J R Chen; D Chow
Journal:  Pharm Res       Date:  1989-05       Impact factor: 4.200

Review 4.  VP16-213 (etoposide). A critical review of its activity.

Authors:  F Cavalli
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 5.  The clinical pharmacology of VM26 and VP16-213. A brief overview.

Authors:  P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 6.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

Review 7.  Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics.

Authors:  J J Holthuis
Journal:  Pharm Weekbl Sci       Date:  1988-06-17

Review 8.  The podophyllotoxin derivatives VP16-213 and VM26.

Authors:  B F Issell
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 9.  Current development of podophyllotoxins.

Authors:  R Canetta; P Hilgard; S Florentine; P Bedogni; L Lenaz
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 10.  Pharmacokinetic optimisation of treatment with oral etoposide.

Authors:  Giuseppe Toffoli; Giuseppe Corona; Barbara Basso; Mauro Boiocchi
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.